News | August 26, 2021
Strong show in domestic formulations business by Indian pharma in Q1FY22: Ind-Ra
Domestic business was up 41.9% YoY and 27.7% QoQ
Domestic business was up 41.9% YoY and 27.7% QoQ
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
Anti-malaria API facility will be operational in 15-18 months
Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg
In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace
Arch Pharma Labs has filed the application
Robust demand for the product across the Middle East, Africa and Latin America
The govt has rolled out three schemes for promoting the manufacture of API
Turnover of API division of ISLL stood at Rs 856.58 crore
Subscribe To Our Newsletter & Stay Updated
